Safety of RSV Preventive Monoclonal Antibody

PHASE4RecruitingINTERVENTIONAL
Enrollment

524

Participants

Timeline

Start Date

October 2, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

April 30, 2026

Conditions
FeverAdverse Event Following Immunisation
Interventions
DRUG

Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody

ACIP Recommended Preventive Monoclonal Antibody

Trial Locations (6)

10027

NOT_YET_RECRUITING

Columbia University, New York

27710

RECRUITING

Duke University, Durham

30322

RECRUITING

Emory University, Atlanta

30333

ACTIVE_NOT_RECRUITING

Centers for Disease Control and Prevention, Atlanta

45229

NOT_YET_RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

94612

NOT_YET_RECRUITING

Kaiser Permanente Northern California, Oakland

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

collaborator

Columbia University

OTHER

collaborator

Emory University

OTHER

collaborator

Kaiser Permanente

OTHER

lead

Duke University

OTHER

NCT07158814 - Safety of RSV Preventive Monoclonal Antibody | Biotech Hunter | Biotech Hunter